(Q41166747)

27 September 2017

Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine (English)

1 reference

27 September 2017

phase I clinical trial

0 references

author name string

R Grunewald

1

1 reference

27 September 2017

J L Abbruzzese

2

1 reference

27 September 2017

P Tarassoff

3

1 reference

27 September 2017

W Plunkett

4

1 reference

27 September 2017

1 January 1991

1 reference

Cancer Chemotherapy and Pharmacology

27 September 2017

1 reference

27 September 2017

27

1 reference

27 September 2017

258-262

1 reference

27 September 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1007/bf00685109

27 September 2017

0 references

cites work

Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia

1 reference

12 December 2020

Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia.

1 reference

12 December 2020

Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C

1 reference

12 December 2020

Metabolism of 1-beta-D-arabinofuranosylcytosine in human leukemic cells

1 reference

12 December 2020

Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine

1 reference

12 December 2020

Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy

1 reference

12 December 2020

Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine

1 reference

12 December 2020

Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia

1 reference

12 December 2020

Variation in sensitivity of DNA synthesis to ara-C in acute myeloid leukaemia

1 reference

12 December 2020

Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).

1 reference

12 December 2020

In-vitro studies on phosphorylation and dephosphorylation of cytosine arabinoside in human leukemic cells

1 reference

12 December 2020

Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia

1 reference

12 December 2020

Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides

1 reference

12 December 2020

Pharmacologically directed ara-C therapy for refractory leukemia.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00685109

1 reference

Dimensions Publication ID

27 September 2017

0 references

1 reference